CROSSJECT Stock Euronext Paris
Stocks
FR0011716265
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
End-of-day quote
Euronext Paris
|
||
| - EUR | - |
|
| 09-23 | CROSSJECT Aligns ZEPIZURE Pediatric Development Plan With BARDA And FDA | CI |
| 05-26 | Crossject: The last round of financing? | AL |
| Market Cap | 72.41M 82.38M 68.21M 62.33M 116M 7.91B 118M 817M 317M 4.03B 309M 303M 13.08B | P/E 2026 * |
3.24x | P/E 2027 * | 2.56x |
|---|---|---|---|---|---|
| Enterprise Value | 54.51M 62.02M 51.34M 46.93M 87.69M 5.95B 88.46M 615M 239M 3.03B 233M 228M 9.85B | EV / Sales 2026 * |
0.9x | EV / Sales 2027 * | 0.39x |
| Free-Float |
92.46% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 2001-08-07 | |
Lionel Seltz
DFI | Director of Finance/CFO | - | 2026-03-24 |
Tony C. Tipton
PRN | Corporate Officer/Principal | - | 2024-08-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Philippe Monnot
CHM | Chairman | 67 | 2009-06-25 |
Eric Nemeth
BRD | Director/Board Member | 67 | - |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.82% | +1.37% | +163.56% | +454.21% | 106M | |
| -1.81% | -5.15% | -24.50% | -46.61% | 99.74M | |
| +1.37% | +0.30% | -16.88% | -65.45% | 81.38M | |
| +3.07% | +8.39% | +36.59% | +26.32% | 73.56M | |
| Average | +2.61% | -1.32% | +39.69% | +92.11% | 90.18M | |
| Weighted average by Cap. | +2.73% | -1.88% | +44.95% | +111.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 60.8M 69.17M 57.27M 52.34M 97.81M 6.64B 98.66M 686M 266M 3.38B 260M 254M 10.98B | 65.2M 74.18M 61.41M 56.13M 105M 7.12B 106M 736M 286M 3.63B 278M 272M 11.78B |
| Net income | 28.3M 32.2M 26.66M 24.36M 45.53M 3.09B 45.92M 319M 124M 1.58B 121M 118M 5.11B | 35.6M 40.5M 33.53M 30.65M 57.27M 3.89B 57.77M 402M 156M 1.98B 152M 149M 6.43B |
| Net Debt | -17.9M -20.36M -16.86M -15.41M -28.8M -1.95B -29.05M -202M -78.42M -997M -76.45M -74.79M -3.23B | -47M -53.47M -44.27M -40.46M -75.61M -5.13B -76.27M -530M -206M -2.62B -201M -196M -8.49B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
